Stoke Therapeutics (STOK) Liabilities and Shareholders Equity (2018 - 2026)

Stoke Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $443.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 8.94% year-over-year to $443.3 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 25.55% YoY), while the FY2025 annual figure was $418.4 million, up 54.09% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $443.3 million, up from $418.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $443.3 million in Q1 2026, with the low at $205.2 million in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $293.3 million (2024), against an average of $308.8 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity retreated 27.19% in 2024, then soared 98.31% in 2025.
• Stoke Therapeutics' Liabilities and Shareholders Equity stood at $256.1 million in 2022, then dropped by 10.83% to $228.3 million in 2023, then increased by 18.92% to $271.6 million in 2024, then jumped by 54.09% to $418.4 million in 2025, then grew by 5.94% to $443.3 million in 2026.
• Business Quant data shows STOK's Liabilities and Shareholders Equity at $443.3 million in Q1 2026, $418.4 million in Q4 2025, and $360.3 million in Q3 2025.